CN116120287B - 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 - Google Patents

作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 Download PDF

Info

Publication number
CN116120287B
CN116120287B CN202310088017.6A CN202310088017A CN116120287B CN 116120287 B CN116120287 B CN 116120287B CN 202310088017 A CN202310088017 A CN 202310088017A CN 116120287 B CN116120287 B CN 116120287B
Authority
CN
China
Prior art keywords
mixture
azabicyclo
hex
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310088017.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116120287A (zh
Inventor
M·埃克哈特
M·吉鲁
E·朗科普夫
C·迈尔
H·瓦格纳
D·威登迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN116120287A publication Critical patent/CN116120287A/zh
Application granted granted Critical
Publication of CN116120287B publication Critical patent/CN116120287B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202310088017.6A 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 Active CN116120287B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20157259.1 2020-02-13
EP20157259 2020-02-13
PCT/EP2021/053286 WO2021160718A1 (en) 2020-02-13 2021-02-11 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
CN202180011395.3A CN115052873A (zh) 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180011395.3A Division CN115052873A (zh) 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物

Publications (2)

Publication Number Publication Date
CN116120287A CN116120287A (zh) 2023-05-16
CN116120287B true CN116120287B (zh) 2025-01-28

Family

ID=69591572

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310088017.6A Active CN116120287B (zh) 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
CN202180011395.3A Pending CN115052873A (zh) 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180011395.3A Pending CN115052873A (zh) 2020-02-13 2021-02-11 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物

Country Status (22)

Country Link
US (3) US11760745B2 (https=)
EP (1) EP4103562A1 (https=)
JP (3) JP7230277B2 (https=)
KR (1) KR20220141333A (https=)
CN (2) CN116120287B (https=)
AR (2) AR121341A1 (https=)
AU (1) AU2021218952A1 (https=)
BR (1) BR112022013979A2 (https=)
CA (1) CA3168690A1 (https=)
CL (2) CL2022002101A1 (https=)
CO (1) CO2022011254A2 (https=)
CR (2) CR20220382A (https=)
DO (2) DOP2022000157A (https=)
EC (1) ECSP22062410A (https=)
IL (2) IL320007A (https=)
JO (1) JOP20220186A1 (https=)
MX (3) MX2022009941A (https=)
PE (2) PE20231985A1 (https=)
SA (1) SA522440127B1 (https=)
TW (2) TWI873290B (https=)
UA (1) UA130722C2 (https=)
WO (1) WO2021160718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839711A (zh) 2018-10-10 2021-05-25 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202144331A (zh) 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2025001956A1 (zh) * 2023-06-30 2025-01-02 远森制药（杭州）有限公司 杂芳族甲酰胺类化合物及其在医药上的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636001A (zh) * 2002-02-20 2005-07-06 拜尔作物科学有限公司 2－氨基－4－二环氨基－6h－1,3,5－三嗪,其制备方法以及其作为除草剂和植物生长调节剂的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DE10230012A1 (de) * 2002-07-04 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 5,6-Dihydro-4H-imidazo[4,5,1-ij]chinoline,ihre Herstellung und ihre Verwendung als Arzneimittel
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP2005089362A (ja) 2003-09-17 2005-04-07 Sumitomo Chemical Co Ltd アリールピラゾリン化合物及びその用途
EP2259679A4 (en) 2008-01-31 2011-09-14 Joslin Diabetes Ct METHODS OF TREATING KALLIKREIN RELATED DISORDERS
NZ602266A (en) * 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
EP2999697B1 (en) 2013-05-23 2017-04-19 Kalvista Pharmaceuticals Limited Heterocyclic derivates
US10981893B2 (en) 2015-07-01 2021-04-20 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3368524B1 (en) 2015-10-27 2021-08-18 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2017072020A1 (en) 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
US10501440B2 (en) 2017-04-21 2019-12-10 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CA3063934A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
JP6828191B2 (ja) 2018-08-16 2021-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202144331A (zh) 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636001A (zh) * 2002-02-20 2005-07-06 拜尔作物科学有限公司 2－氨基－4－二环氨基－6h－1,3,5－三嗪,其制备方法以及其作为除草剂和植物生长调节剂的应用

Also Published As

Publication number Publication date
US20210292301A1 (en) 2021-09-23
TWI873290B (zh) 2025-02-21
MX2025013435A (es) 2025-12-01
SA522440127B1 (ar) 2025-04-06
CN116120287A (zh) 2023-05-16
US20240002363A1 (en) 2024-01-04
MX2025013436A (es) 2025-12-01
DOP2022000157A (es) 2022-09-15
JP2022543494A (ja) 2022-10-12
EP4103562A1 (en) 2022-12-21
IL295125B2 (en) 2025-09-01
MX2022009941A (es) 2022-09-12
CA3168690A1 (en) 2021-08-19
US11760745B2 (en) 2023-09-19
US20240076286A1 (en) 2024-03-07
BR112022013979A2 (pt) 2022-10-11
IL295125B1 (en) 2025-05-01
JP2023067881A (ja) 2023-05-16
WO2021160718A1 (en) 2021-08-19
AR131110A2 (es) 2025-02-19
JP2025148369A (ja) 2025-10-07
CR20250167A (es) 2025-05-23
AR121341A1 (es) 2022-05-11
AU2021218952A1 (en) 2022-07-28
TW202535863A (zh) 2025-09-16
CR20220382A (es) 2022-09-16
IL295125A (en) 2022-09-01
KR20220141333A (ko) 2022-10-19
ECSP22062410A (es) 2022-09-30
CL2022002101A1 (es) 2023-01-27
JP7703587B2 (ja) 2025-07-07
US12479827B2 (en) 2025-11-25
CN115052873A (zh) 2022-09-13
UA130722C2 (uk) 2026-04-29
DOP2023000195A (es) 2023-10-31
CL2023001244A1 (es) 2023-11-03
IL320007A (en) 2025-06-01
JOP20220186A1 (ar) 2023-01-30
PE20231985A1 (es) 2023-12-12
JP7230277B2 (ja) 2023-02-28
CO2022011254A2 (es) 2022-08-19
PE20221591A1 (es) 2022-10-10
TW202144330A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CN116120287B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
EP3368529B1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN113039181B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP7175914B2 (ja) 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体
CN115087652B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP7378470B2 (ja) 血漿カリクレイン阻害剤としてのフェニルテトラゾール誘導体
TW202233592A (zh) 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
EA049265B1 (ru) Гетероароматические карбоксамидные производные в качестве ингибиторов калликреина плазмы
BR122025021106A2 (pt) Compostos derivados de carboxamida heteroaromáticos como inibidores da calicreína plasmática, sal dos mesmos, composição farmacêutica compreendendo os mesmos, e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant